BioCryst Pharmaceuticals, Inc. (BCRX) is in Healthcare, Drug Manufacturers - Specialty & Generic, based in United States, listed on NasdaqGS. Market cap 2.12B USD. 52-week range 6.00 to 11.22 USD. Trailing P/E 7.3. Data as of 2026-10-09.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in ...